Drug Profile
Research programme: CXCR4 inhibitors - Biokine
Alternative Names: BKT-170Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Biokine Therapeutics
- Class
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypertrophic scars; Inflammation
- Discontinued Cancer
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Hypertrophic-scars in Israel (Topical, Gel)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Hypertrophic-scars in Israel (Topical, Paste)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Inflammation in Israel (Topical, Gel)